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an alternative fuel source. During these shifts in metabolism, seizures are controlled in patients. Although ketone bodies have been postulated to play a therapeutic role, seizure control is poorly correlated with ketone body levels. 1, 2 Thus, despite the relative success of the diet, the precise mechanism of action of the MCT KD remains unknown. However, there is a growing interest in the potential effects on seizures of the medium-chain octanoic (C8) and decanoic (C10) acids, which are known to accumulate in the plasma of patients receiving the MCT KD. 3, 4 Despite both these fatty acids being present in the MCT KD and in patient plasma, evidence is now emerging to suggest that C10, and not C8, may be responsible for the beneficial effects associated with the MCT KD. Thus C10, and not C8, has previously been reported by us to elicit peroxisome proliferator-activated receptor-c (PPARc)-dependent increases in neuronal mitochondrial content, and complex I and catalase activity. 5 These findings, coupled with the direct inhibitory effect of C10 on a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, 6 provide mechanistic evidence whereby C10 could elicit seizure control. The antiseizure properties of C10 are further supported by observations, in vivo, that mice fed with a C10-enriched chow display significantly improved seizure tolerance and brain antioxidant capacity. [7] [8] [9] [10] [11] In studies conducted by Wla z et al., 9, 10 C10 levels were also determined in the brains of mice following C10-enriched feeding. Interestingly, the concentration of C10 in mouse brain was found to average 240-250 lM, corresponding with therapeutic levels reported in patient plasma on the MCT KD, as well as the optimum concentration (250 lM) for mitochondrial proliferation in our previous studies. 5, 12 Currently, MCT oils used in the MCT KD are varying mixtures of C8 and C10, the ratios of which differ from product to product. 13 This diet is generally favored due to its ability to provide energy and generate ketones with a lower total fat intake compared to long-chain triglyceride-based diets, thus improving palatability. 14, 15 However, as medium-chain fatty acids are usually rapidly oxidized or converted to ketone bodies, how can sufficient levels of C10 accumulate in the brain to permit the fatty acid to exert its effects on targets, such as the PPARc and AMPA receptor? To address this question, we here assessed the rates of b-oxidation of C8 and C10 in the human SH-SY5Y neuroblastoma cell line, that is, following on from our previous work. 5 A well-characterized cell line, SH-SY5Y cells exhibit a range of neuron-like properties, providing a suitable model for this study. Furthermore, as C10 appears to be a key component in regard to understanding the mechanisms of the MCT KD, we also investigated whether C8 exerts any sparing effect concerning C10 b-oxidation.
Methods

Materials
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich (Poole, United Kingdom 
Cell culture
SH-SY5Y cells were utilized between passages 20-24 for all experimental procedures. Cells were cultured in 1:1 DMEM/F12 medium, containing 17.5 mM glucose and supplemented with 100 mL/L heat-inactivated FBS and 10 mL/ L 200 mM L-glutamine. All cells were maintained in a humidified atmosphere at 37°C and 5% CO 2 . Cells were subcultured by washing with 10 mL/flask Mg 2+ /Ca 2+ -free Dulbecco phosphate-buffered saline (DPBS), lifted with 2 mL 0.25% trypsin-EDTA, and suspended in 8 mL culture medium to inactivate the trypsin. The cell suspension was transferred to a falcon tube and centrifuged for 4 min at 500 g. The supernatant was removed and cells were suspended in a known volume of fresh culture medium. Cells were counted using the Trypan blue exclusion test for viability. A known volume of the cell suspension was mixed 1:1 with 0.4% Trypan blue solution and counted with a BioRad TC20 Automated Cell Counter (Hemel Hempstead, United Kingdom). Cells were then seeded at a density of 1 9 10 4 cells/cm 2 in six-well plates, made up to a final volume of 2 mL with fresh medium and cultured for 5 days prior to all experiments. The same starting number of cells was used for each investigation. Medium was refreshed every 2 days.
Key Points
• C10 b-oxidation is markedly lower than that of C8 in neuronal cells Glucose, C10, and C8 b-oxidation in SH-SY5Y cells All experimental procedures were carried out with the use of a specifically formulated DMEM, containing a final concentration of 15 mM hydroxyethylpiperazine ethanesulfonic acid, 2.9 mM sodium bicarbonate, 2 mM L-glutamine, 0.5 mM sodium pyruvate, and 21.5 lM phenol red. A stock solution of 134.3 mM [U- 13 C]glucose was prepared by dissolving glucose in DMEM solution and then frozen at À20°C in aliquots. Stock solutions of 50 mM [1- 13 C]C10 and 50 mM [1- 13 C]C8 were prepared in dimethylsulfoxide (DMSO), sterile-filtered, and then stored in aliquots at À20°C.
On day 5 of culture, complete growth medium was removed and cells were washed once with DPBS. Cells were then incubated with 2 mL of the DMEM formula, supplemented with 10% FBS and 3 mM D-glucose, for 20 h at 37°C and 5% CO 2 . After 20 h, the medium was removed and cells were washed once with DPBS. To each well, 3 mL of DMEM was then added, containing 3 mM [U- 13 C]glucose and vehicle control DMSO, or 3 mM D-glucose with either 250 lM [1-
13 C]C8. Wells were then sealed with a 3-mL layer of heavy mineral oil to prevent the loss of 13 CO 2 through gas exchange between the medium and the atmosphere. 16 Using this approach, we were able to demonstrate negligible (<0.1%) loss of label from the medium. Cells were incubated at 37°C for 6 h, with 100 lL of medium sampled from each well at hourly intervals. Sampled medium was immediately stored in rubber-sealed Exetainer vials (Labco, Ceredigion, United Kingdom) and kept at À20°C until analysis.
C10 and C8 coincubation
The effects of coincubating C10 and C8 on C10 b-oxidation in SH-SY5Y cells were also explored. Additional stock solutions of 25 mM C8 and 100 mM [1- 13 C]C10 were prepared in DMSO, sterile-filtered, and stored in aliquots at À20°C. Cells were cultured and incubated for 20 h in 10% FBS-supplemented DMEM containing 3 mM D-glucose, as previously described. Medium was then removed and cells were washed. Medium was then replaced with 3 mL DMEM containing either 3 mM [U- 13 C]glucose and vehicle control DMSO, or 3 mM unlabeled D-glucose. In each D-glucosesupplemented well, cells were treated with either a final concentration of 250 lM [1-
13 C]C10, or 250 lM [1-13 C]C10 plus 62.5 lM C8, at a fixed total volume. Wells were then sealed with heavy mineral oil, cells were incubated, and medium was sampled as previously outlined.
Preparation of [U-
13 C]C16 [U- 13 C]C16 was neutralized with 0.35 M NaOH and made to a concentration of 17.5 mM in water, before heating to 70°C until fully dissolved. Fatty acid-free bovine serum albumin (BSA) was then dissolved to a concentration of 3.5 mM in water at 37°C. Swirling gently, [U- 13 C]C16 was then slowly added 1:1 to BSA at 37°C, forming an 8.75-mM [U- 13 C]C16:BSA complex (5:1 molar ratio fatty acid:BSA). An additional stock solution of 1.75 mM BSA in water was also prepared. Both solutions were aliquoted and stored at À20°C until further use.
Carnitine palmitoyltransferase I inhibition assay
A stock solution of 50 mM etomoxir was prepared in sterile cell culture grade water and stored in aliquots at À20°C. On day 5 of culture, growth medium was replaced with 2 mL DMEM formula containing 3 mM D-glucose and 10% FBS. Cells were incubated with or without the presence of 50 lM etomoxir, for 20 h at 37°C and 5% CO 2 . Medium was then removed and replaced with 3 mL DMEM, containing 3 mM [U- 13 C]glucose and vehicle control DMSO or 3 mM D-glucose with 250 lM of either [1-
13 C]C16, with 50 lM etomoxir also added to previously exposed cells. Wells were then sealed with heavy mineral oil, with cells incubated and medium sampled as previously described.
Measurement of
13 CO 2 release Samples were thawed at room temperature, and 100 lL 1M hydrochloric acid was injected through the septum into each vial to release CO 2 from the medium. Vials were centrifuged for 30 s at 500 g. Samples were then analyzed on a GasBench II coupled to a Thermo Delta-XP isotope-ratio mass spectrometer (Thermo-Finnigan, Bremen, Germany). Ten repeat injections were carried out per sample, with 13 CO 2 / 12 CO 2 ratios measured against Vienna Pee Dee Belemnite (VPDB) using a calibrated CO 2 reference gas. Following this, 13 CO 2 / 12 CO 2 ratios were then converted to mole percent excess using absolute molar ratio of 13 C to 12 C (0.0111796) in VPDB. The change in mole percent excess was then converted to pmol CO 2 generated using the volume of medium and concentration of bicarbonate (2.9 mM) present, which was then corrected for the number of labeled carbon atoms (1 for C8 and C10, 6 for glucose, and 16 for palmitate) to obtain picomoles of substrate oxidized.
Cell viability
Cells were incubated for 20 h at 37°C and 5% CO 2 with 50 lM etomoxir in DMEM supplemented with 10% FBS, and then a further 6 h at 37°C with 50 lM etomoxir in DMEM without FBS. Cells were then lifted from wells with 1 mL 0.25% trypsin-EDTA, suspended in 4 mL culture medium, and centrifuged for 4 min at 500 g. Supernatant was removed, and cells were suspended in 1 mL of fresh culture medium. Viability of cells was then tested using the Trypan blue exclusion test.
Statistical analysis
Data are expressed as mean AE standard deviation, with n indicating the number of independent experiments carried out. Statistical analysis between two groups was performed using a Student t test, whereas analysis of three groups or Results b-oxidation rates of glucose, C8, and C10 in SH-SY5Y cells 13 C-labeled compounds permit the measurement of cellular b-oxidation rates of glucose, C8, or C10 via CO 2 release emanating from pyruvate dehydrogenase activity and/or the tricarboxylic acid (TCA) cycle. 13 CO 2 release over 6 h was used to determine and quantify the rate of cellular b-oxidation of each compound. Cells were treated with 3 mM 13 C-labeled glucose, to replicate physiological levels observed in patients under the MCT KD. 13 C-labeled C10 and C8 were added separately to a final concentration of 250 lM, this being the concentration of C10, previously determined by us, 5 for optimum effects upon mitochondria and antioxidant status. Furthermore, this replicates the brain concentration achieved following peripheral C10 administration.
9,10 Unlabeled 3 mM glucose was used in the presence of 13 C-labeled C10 and C8. 13 CO 2 release, for each molecule studied, was linear for the 6-h incubation. As expected, the rate of glucose oxidation was markedly faster than that of either C8 or C10 (Fig. 1A) . However, C8 and C10 were found to be differentially oxidized in these cells, with C10 b-oxidation significantly lower than that of C8, by approximately 80% (Fig. 1A) . This suggests that C8 may be preferentially oxidized in SH-SY5Y cells.
Effect of coincubation of C8 and C10 on b-oxidation
Current MCT KD preparations are composed of a mixture of C8 and C10 at varying ratios. In light of this, we examined the effects on [1- 13 C]C10 b-oxidation when SH-SY5Y cells were treated with 62.5 lM unlabeled C8, reflecting the move toward a more C10-enriched formula, that is, with C8 compromising only 20% of the total fatty acids. Despite the relatively low concentration, C8 addition was found to significantly impair the b-oxidation rate of C10 by 29% (Fig. 1B) .
C10 b-oxidation following carnitine palmitoyltransferase I inhibition
To determine the mechanisms behind the differential b-oxidation of C8 and C10, the potential role of the carnitine shuttle was explored. Whereas long-chain fatty acids require this system, medium-chain fatty acids are generally considered to be able to enter the mitochondrial matrix in a carnitine-independent manner. 17 Although this may be the case for C8, there are reports to suggest that C10, in contrast to C8, may require the carnitine system for complete mitochondrial b-oxidation. 18 Carnitine palmitoyltransferase I (CPT1) is responsible for transferring fatty acyl groups to carnitine and is the rate-limiting step in carnitine-dependent b-oxidation in mitochondria. [19] [20] [21] To evaluate the potential role of CPT1 in C8 and C10 b-oxidation, the well-characterized CPT1 irreversible inhibitor etomoxir was used. [22] [23] [24] Through dose-response experiments, [U-
13 C]C16 acid, which is well-known to depend on CPT1 for mitochondrial b-oxidation, was used as a positive control to allow us to determine the maximal concentration (50 lM) of etomoxir that could be used to inhibit CPT1 without affecting cell viability (100 lM etomoxir caused cell death as judged by Trypan blue exclusion). With the conditions employed, b-oxidation of [U- 13 C]C16 was reduced by 99%, suggesting complete irreversible inhibition of CPT1 (Table 1) . Moreover, etomoxir was observed to have no effect on viability of the SH-SY5Y cells used (data not shown). Under the same conditions, C10 b-oxidation was found to be reduced by 95% in the presence of etomoxir (Table 1) , whereas C8 b-oxidation was only inhibited by 34%. 
Discussion
There is growing interest in the mode of action of the MCT KD and, in particular, the effects of the constituent medium-chain fatty acid, C10. In contrast to C8, C10 appears to have a number of biological targets that can explain the antiseizure properties of the diet. However, critical for C10 to exert its beneficial effects is attainment of a sufficiently high concentration within the brain. Existing data, including those generated from our own laboratory, suggest concentrations of up to 250 lM C10 are required to facilitate an increase in mitochondrial biogenesis, increased antioxidant capacity, and AMPA receptor inhibition. 5, 6, 12 However, such a concentration appears achievable, as oral administration of C10 to mice leads to brain concentrations of up to 250 lM.
9,10 Medium-chain fatty acids are catabolized by b-oxidation, resulting in acetyl CoA formation. This can be further metabolized to generate ketones and/or enter the TCA cycle. Since medium-chain fatty acids are able to cross the blood-brain barrier [25] [26] [27] and the enzymes of b-oxidation are reported to be present in neuronal cells, 28, 29 we have in this study evaluated the ability of neuronal-like SH-SY5Y cells to b-oxidize C8 and C10. We hypothesized that C10 would be relatively spared, which may result in a degree of accumulation of this fatty acid.
The use of 13 C-labeled substrates allows for the metabolism of substrates to be compared, that is, by capturing and quantifying the labeled CO 2 released by the cells. Using this approach, metabolism of glucose was considerably greater than that for C8 or C10. This was expected, given that it is well established that glucose is the main fuel for neuronal energy metabolism. [30] [31] [32] [33] Despite showing lower rates of oxidation than glucose, both C8 and C10 were b-oxidized to some extent by the cells. However, our observation that C10 b-oxidation was markedly lower than that of C8 suggests that these two fatty acids are processed differently by SH-SY5Y cells. To ascertain the potential cause for this difference, we considered the involvement of the carnitine shuttle, as C10 is reported to utilize this system for maximal b-oxidation to occur. 18 Furthermore, C10 oxidation is impaired in inherited disorders of carnitine metabolism. 34 This reliance of C10 upon the carnitine shuttle is further supported here by our finding that CPT1 inhibition, by etomoxir, markedly impairs C10 b-oxidation, whereas C8 b-oxidation appeared mainly CPT1-independent. Although etomoxir is a very well-characterized CPT1 inhibitor, as reflected by its ability to almost completely abolish C16 b-oxidation, it should be noted that it may have other targets, for example, by acting as a PPARa agonist. Thus, relatively prolonged exposure (5 days) has been suggested to lead to upregulation of fatty acid oxidation. 35 However, in our acute study, the converse was apparent, that is, in keeping with CPT1 inhibition. Our finding that CPT1 inhibition markedly impairs C10 b-oxidation, whereas C8 b-oxidation was mainly CPT1-independent, supports the need for this system in neuronal type cells, that is, if maximal catabolism of the fatty acid is to occur.
To further explore the potential common metabolic fates of C8 and C10, we looked at the effect of the presence of C8 on C10 b-oxidation. Even in the presence of a relatively low concentration of C8, C10 b-oxidation was significantly inhibited. This observation may suggest that in the MCT KD, the presence of C8 has a sparing effect to further limit the catabolism of C10, thus facilitating its accumulation in the brain and the manifestation of its antiseizure effects. However, it is possible that other mechanisms could also contribute to the differential metabolism of C8 and C10, for example, varying degrees of cellular uptake for the two fatty acids. Further studies, involving cellular fractionation following C8 and/or C10 exposure, may therefore be informative.
To summarize, the data presented here suggest that in a neuronal cell line, C10 and C8 are differentially oxidized. Thus, C8 may be preferentially metabolized and provide energy, whereas, because of its requirement of the carnitine shuttle, C10 is metabolized at a lower rate and can consequently accumulate (Fig. 2) . CPT1 activity in brain is low, and although there is also a brain-specific isoform of CPT1 (CPT1c), this isoform has not been found to demonstrate any significant enzymatic activity. 21, [36] [37] [38] [39] This hypothesis is further supported by the recent observation that reports, in astrocytes, that C8 is ketogenic whereas C10 is not. 40 In conclusion, the fatty acid components of the MCT KD are differentially metabolized by neuronal-like cells. The carnitine dependence and sluggish metabolism of C10 provides an explanation for how critical concentrations may occur and permit interaction with key antiseizure targets. In contrast, C8 may be preferentially metabolized and have two key effects: sparing of C10 by inhibiting C10 b-oxidation and acting as a fuel source for brain energy metabolism. Cells were pretreated for 20 h with the irreversible CPT1 inhibitor etomoxir (50 lM) and then incubated for 6 h with 13 C-labeled 250 lM C8, C10, or C16:bovine serum albumin in the presence of 50 lM etomoxir. Control cells were processed identically but were pretreated and incubated in the absence of etomoxir.
CPT1 inhibition resulted in a significant reduction in C10 b-oxidation by 95%. The b-oxidation rate of C8 was also significantly reduced by 34%. Results are expressed as mean AE SD of five independent experiments, each performed in duplicate. CPT1 inhibition was confirmed with a significant 99% inhibition of [U- 13 C]C16 oxidation. Results are expressed as mean AE SD of three independent experiments, each performed in duplicate.
C8, octanoic acid; C10, decanoic acid; C16, palmitic acid; CPT1, carnitine palmitoyltransferase I; SD, standard deviation. Although this study provides further mechanistic insight into the MCT KD, relevance to understanding the classical KD is not immediately clear. However, the possibility exists that progressive (mitochondrial/peroxisomal) oxidation of the long-chain fatty acid components occurs, leading to C10 formation and eventual neuronal C10 accumulation. Further work is clearly needed to test this hypothesis. Additional alternative mechanisms could also be responsible for efficacy of the classical KD. Decanoic acid (C10) and octanoic acid (C8) have differential effects in regard to potential seizure control; for example, C10 acts as a peroxisome proliferator-activated receptor-c (PPARc) agonist, eliciting improvement in mitochondrial function. For this to occur, a sufficient neuronal concentration of C10 is required. It is proposed that due to its reliance on the carnitine shuttle, b-oxidation of C10 is relatively slow, permitting accumulation of this fatty acid. In contrast, C8 oxidation may proceed largely in the absence of the carnitine system, contributing to b-oxidation and cellular energy metabolism. In addition, C8 may inhibit any C10 b-oxidation, further contributing to its accumulation. CAT, carnitine-acylcarnitine translocase; CoA, acyl-coenzyme A; CPT1, carnitine palmitoyltransferase I; CPT2, carnitine palmitoyltransferase II; IMM, inner mitochondrial membrane; OMM, outer mitochondrial membrane. Epilepsia ILAE
